QL1706 treatment for advanced bone and soft tissue sarcoma

Efficacy and Safety of QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma: a Phase II Clinical Study

This will try QL1706 in adults with advanced or metastatic bone and soft tissue sarcomas to see if it controls tumor growth and is well tolerated.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Sun Yat-sen University (Academic / other)
• Drugs / interventions: chemotherapy, radiation, methotrexate, cyclophosphamide, prednisone
• Locations: 1 site (Guangzhou, Guangdong)
• Trial ID: NCT06939855 on ClinicalTrials.gov

What this trial studies

This is a single-center, open-label Phase 2 trial of QL1706, a bispecific antibody targeting PD-1 and CTLA-4, in patients with unresectable locally advanced or metastatic bone and soft tissue sarcomas. After screening, participants receive QL1706 5 mg/kg by IV infusion every 3 weeks until disease progression or unacceptable toxicity, followed by a safety follow-up period. Efficacy (tumor response and disease control) and safety are monitored throughout treatment. The protocol enrolls multiple sarcoma histologies, with some subtypes allowed to be treatment-naïve and others having prior standard systemic therapy as appropriate.

Who should consider this trial

Good fit: Adults aged 18–75 with histologically confirmed unresectable locally advanced or metastatic bone or soft tissue sarcoma (including undifferentiated sarcoma, leiomyosarcoma, myxofibrosarcoma, alveolar soft part sarcoma, pleomorphic undifferentiated sarcoma, chordoma, angiosarcoma, and dedifferentiated liposarcoma) who can attend the Guangzhou site and meet protocol requirements are ideal candidates.

Not a fit: Patients with sarcoma subtypes not listed, those unable to travel to the single study site, those with contraindications to immune checkpoint therapy, or those previously treated with PD‑1/PD‑L1 agents when prior PD‑1 therapy is excluded may not receive benefit.

Why it matters

Potential benefit: If successful, QL1706 could shrink tumors or slow progression and offer a new treatment option for some patients with advanced sarcoma.

How similar studies have performed: Dual PD‑1 and CTLA‑4 blockade has shown activity in some sarcoma subtypes in prior combination trials, but bispecific agents like QL1706 are relatively new and have limited published data.

Eligibility criteria

Inclusion Criteria:

1. Subjects voluntarily participate in the study, sign the informed consent form (ICF), and are able to comply with study procedures.
2. Age ≥18 years and ≤75 years at the time of signing ICF, regardless of gender.
3. Histologically confirmed unresectable locally advanced or metastatic bone and soft tissue sarcoma at this institution, including: undifferentiated sarcoma, leiomyosarcoma, myxofibrosarcoma, alveolar soft part sarcoma, pleomorphic undifferentiated sarcoma, chordoma, angiosarcoma, and dedifferentiated liposarcoma.
4. For histological subtypes without standard systemic therapy, such as chordoma, prior systemic therapy is not required. Subjects with alveolar soft part sarcoma may be systemic therapy-naïve or have received systemic therapy excluding PD-1/PD-L1 inhibitors.
5. For histological subtypes with standard systemic therapy, such as undifferentiated sarcoma, leiomyosarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, and pleomorphic undifferentiated sarcoma, subjects must have received anthracycline-based chemotherapy. Subjects with angiosarcoma must have received paclitaxel- or anthracycline-based chemotherapy, and have developed metastasis or disease progression (≥10% increase in the sum of the longest diameters within 3 months), or be intolerant to standard therapy.
6. At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
7. Subjects are able to provide tumor tissue samples and blood samples for biomarker testing including PD-L1.
8. ECOG performance status of 0-1, with an expected survival ≥12 weeks.
9. Clinical laboratory tests at screening must meet the following criteria (no use of blood components, hematopoietic growth factors, leukocyte- or platelet-stimulating agents, or anemia-correcting medications within 14 days before testing):

   1. Hematologic: Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L; Platelet count (PLT) ≥90 × 10⁹/L; Hemoglobin (Hb) ≥90 g/L.
   2. Hepatic function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN); for subjects with liver metastasis, AST and ALT ≤5 × ULN. Total bilirubin (TBIL) ≤1.5 × ULN (subjects with Gilbert syndrome: TBIL \<3 × ULN). Albumin (ALB) ≥30 g/L.
   3. Renal function: Serum creatinine (Cr) ≤1.5 × ULN or creatinine clearance (CCr) ≥50 mL/min (calculated by Cockcroft-Gault formula).
   4. Coagulation: Activated partial thromboplastin time (APTT) ≤1.5 × ULN; International normalized ratio (INR) ≤1.5; Prothrombin time (PT) ≤1.5 × ULN.
   5. Urine protein: Urine protein dipstick ≤1+. If ≥2+, a 24-hour urine protein test is required; subjects with \<1 g/day are eligible.
   6. Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%.
10. Female subjects must be non-lactating, and a pregnancy test must be negative before enrollment.
11. Subjects of childbearing potential agree to use effective contraception from signing the ICF through at least 180 days after the last dose of study drug.

Exclusion Criteria:

1. Known history of severe allergic reactions to any monoclonal antibody or any excipient in its formulation.
2. Currently participating in and receiving investigational treatment, or participation in an investigational drug/device study with investigational treatment administered within 4 weeks before the first dose of study treatment.
3. History of other active malignancies within 5 years prior to first dose. Cured localized malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast are not restricted by time.
4. Prior treatment with immune checkpoint inhibitors (PD-1/PD-L1 agents) or other agents targeting T-cell receptor signaling (for example CTLA-4, OX-40). Subjects treated more than 5 years earlier and with no clinical evidence of disease recurrence within the past 5 years may be eligible.
5. Presence of brain metastasis. Subjects with asymptomatic brain metastasis or symptomatic metastasis that is stable for ≥4 weeks after treatment may be enrolled.
6. Active autoimmune disease requiring systemic therapy (disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to enrollment. Conditions include but are not limited to myasthenia gravis, systemic lupus erythematosus, interstitial lung disease, uveitis, ulcerative colitis, autoimmune hepatitis, hypophysitis, systemic vasculitis, nephritis, hyperthyroidism, hypothyroidism, mixed connective tissue disease. Subjects with vitiligo or fully resolved childhood asthma without intervention in adulthood are eligible. Asthma requiring bronchodilator therapy is not eligible. Physiologic replacement therapy (thyroxine, insulin, or corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy.
7. Active pulmonary tuberculosis, radiation pneumonitis, drug-induced pneumonitis, or other significant pulmonary impairment during screening.
8. Requirement for long-term or high-dose nonsteroidal anti-inflammatory drugs (aspirin ≥325 mg) or anticoagulant therapy.
9. Clinically significant gastrointestinal disorders including, but not limited to, history of gastrointestinal bleeding or perforation, or acute pancreatitis.
10. Cardiovascular or cerebrovascular diseases including:

(1) Heart failure ≥NYHA class II. (2) Severe or unstable angina. (3) Myocardial infarction or cerebrovascular accident within 6 months before first dose, or aortic aneurysm requiring surgical repair.

(4) Atrial fibrillation or clinically significant supraventricular/ventricular arrhythmias requiring treatment.

(5) Symptomatic superior vena cava syndrome. (6) QTc \>450 ms (male) or QTc \>470 ms (female). (7) Hypertension not adequately controlled with medication (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg), or history of hypertensive crisis or hypertensive encephalopathy.

11\. Hereditary or acquired bleeding tendency or coagulation disorders. 12. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage.

13\. Active infection or unexplained fever \>38.5°C during screening. Fever confirmed to be cancer-related may be eligible.

14\. Use of broad-spectrum antibiotics by any route within 30 days before first dose.

15\. Systemic corticosteroid therapy (≥10 mg/day prednisone or equivalent) or other immunosuppressants (such as cyclosporine, cyclophosphamide, azathioprine, methotrexate, thalidomide) within 14 days before first dose, or use of immunostimulatory agents (such as interferons or interleukin-2) within 4 weeks.

16\. Major surgery without fully recovered wound healing, severe fractures, therapeutic clinical trial, or traditional Chinese medicine treatment within 4 weeks before first dose; or use of traditional Chinese medicine within 2 weeks.

17\. Adverse events from prior antitumor therapy not recovered to ≤Grade 1 (alopecia and cancer-related fatigue excepted, neurotoxicity allowed ≤Grade 2).

18\. HIV infection, other acquired or congenital immunodeficiencies, or history of organ or allogeneic bone marrow transplantation (corneal transplantation excepted).

19\. Positive hepatitis B surface antigen (HBsAg) and/or positive hepatitis B core antibody (HBcAb) with HBV DNA \>1×10⁴ copies/mL (approximately \>2000 IU/mL); or positive hepatitis C antibody (HCV-Ab) with HCV-RNA \>1×10³ copies/mL. Subjects with dual positivity for HBsAg and HCV-RNA are excluded.

20\. Receipt of live or attenuated vaccines within 30 days prior to first dose. 21. Known psychiatric disorders, epilepsy, dementia, or alcohol/drug abuse that may affect compliance.

22\. Any condition including medical history, concomitant disease, treatment, or abnormal laboratory results that may confound study results, interfere with participation, or deemed not in the best interest of the subject by the investigator or sponsor.

Where this trial is running

Guangzhou, Guangdong

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)

Study contacts

• Study coordinator: Jin Wang

Conditions Bone and Soft Tissue Tumors; QL1706